Table 4. Univariate and multivariate analysis for OS.
| Variables | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | ||
| Treatment regimen | |||||
| mFOLFIRINOX vs. GEMOX | 0.471 (0.239–0.929) | 0.030 | 0.433 (0.217–0.865) | 0.018 | |
| Age | |||||
| ≥60 vs. <60 | 1.498 (0.772–2.905) | 0.232 | 1.367 (0.652–2.864) | 0.408 | |
| Sex | |||||
| Male vs. female | 0.434 (0.206–0.914) | 0.028 | 0.334 (0.145–0.768) | 0.010 | |
| ECOG | |||||
| 1 vs. 0 | 1.314 (0.661–2.615) | 0.436 | 1.632 (0.720–3.701) | 0.241 | |
| Disease status | |||||
| Metastatic vs. locally advanced | 2.057 (1.020–4.147) | 0.044 | 2.393 (1.102–5.194) | 0.027 | |
| CA 19-9 | |||||
| ≥37 vs. <37 | 0.641 (0.586–2.386) | 0.641 | 0.521 (0.222–1.221) | 0.134 | |
P<0.05 was considered statistically significant. OS, overall survival; HR hazard ratio; ECOG, Eastern Cooperative Oncology Group.